Dr Reddys Laboratories Ltd (RDY) stock
RDYNYSEPharmaceutical PreparationsFiscal year ends March 31
Financials through fiscal 2026, year ended Mar 31, 2026Score 7/30
$14.83−0.15 (-1.00%)
Close on Nov 19, 2026Market cap $12.38BP/E 27.2Yield 0.57%
Dr Reddys Laboratories free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
For fiscal 2026 it was ₹33.43B, up 76.6% from the year before. Over ten years it grew 1.4% a year on average. The highest annual figure on record is ₹47.55B in fiscal 2023.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ₹33.43B | +76.6% |
| FY2025 | Mar 31, 2025 | ₹18.92B | -34.8% |
| FY2024 | Mar 31, 2024 | ₹29.03B | -39.0% |
| FY2023 | Mar 31, 2023 | ₹47.55B | +253.6% |
| FY2022 | Mar 31, 2022 | ₹13.45B | -48.2% |
| FY2021 | Mar 31, 2021 | ₹25.96B | +3.9% |
| FY2020 | Mar 31, 2020 | ₹25.00B | +14.9% |
| FY2019 | Mar 31, 2019 | ₹21.75B | +148.9% |
| FY2018 | Mar 31, 2018 | ₹8.74B | -5.4% |
| FY2017 | Mar 31, 2017 | ₹9.24B | -68.4% |
| FY2016 | Mar 31, 2016 | ₹29.23B | – |
See a number that looks wrong?